Medical Device Procurement: Unravelling the Role of Health Technology Assessment

By Staff Writer

November 13, 2023

The Current State of Health Technology Assessment

Health technology assessment (HTA) in medical device procurement has been instrumental in determining the value of medical devices. However, the unique characteristics of these devices, including frequent iterations and user learning curves, make generalising outcomes challenging. Furthermore, the diverse needs of stakeholders often result in varying views on a technology’s value. Despite the wealth of information available on HTA, a knowledge gap exists regarding its use by non-payer, non-HTA stakeholders in their assessment of medical devices.

Addressing the Gap: The ISPOR Special Interest Group Study

In an attempt to bridge this gap, the ISPOR Medical Devices and Diagnostics Special Interest Group conducted a systematic literature review. These studies were geographically diverse, originating from various locations globally. Two studies each were conducted in the United States, the United Kingdom, and Canada. Other studies were based in Italy, Australia, and South Africa. This review aimed to summarise the current evidence base for the criteria used in medical device procurement.A key finding across all studies was the utilisation of decision-making criteria that are generally considered standard elements of HTA. The most common criteria included cost (reported in 100% of the studies), safety (91%), efficacy (82%), cost-effectiveness (64%), and budget impact (36%). The results, however, showed sparse evidence regarding HTA’s use in device purchasing, making it difficult to draw firm conclusions about HTA’s impact on procurement.

Health Technology Assessment in Medical Device Procurement

The use and impact of HTA on treatment decisions vary widely across different geographies, further complicating the process. However, a growing trend towards “mini” or hospital-level HTA, which directly informs procurement decisions, has been observed. Most hospital-level HTA studies reviewed continue to depend on national-level HTA. They also use published systematic reviews to shape their conclusions.

The ISPOR Special Interest Group anticipates that HTA has more impact than their findings suggest, possibly due to a lack of publication incentive among procurement bodies. We need to deepen our research to comprehend the relationship between HTA and procurement better. Encouraging broader, more systemic evidence-based decision making also requires our attention. 

 

Reference url

Recent Posts

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

Cecolin 9 HPV vaccine
        

Cecolin 9 HPV Vaccine: A Game Changer for Cervical Cancer Prevention in China

🌍 Did you know that China has just achieved a historic milestone in the fight against cervical cancer?

The approval of the Cecolin 9 HPV vaccine, the first domestically developed 9-valent HPV vaccine, marks a transformative moment for public health, enhancing access and affordability across the nation. This development not only meets global health goals but also reshapes the landscape of cervical cancer prevention in China.

Curious to learn how this advancement is set to impact vaccination efforts and healthcare economics? Dive into the full article for deeper insights!

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.